Ipilimumab is an FDA-approved CTLA-4 inhibitor and has been tested in various clinical trials in patients with HNSCC (NCT02369874, NCT02551159, NCT02319044) (73–76). The gene discussed is CTLA4; the disease is head and neck squamous cell carcinoma.